EGFR and non-small cell lung carcinoma: Importantly, approximately 20 to 40% of EGFR-mutated NSCLC patients experience primary resistance to first- or second- generation EGFR-TKIs, commonly attributed to genetic alterations, such as exon 20 insertions and the de novo T790M point mutation [14,15,16,17].